Long-term outcomes of ductal carcinoma in situ of the breast: A systematic review, meta-analysis and meta-regression analysis

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Stuart, Kirsty E ^a,b   Houssami, Nehmat ^c   Taylor, Richard ^a,d   Hayen, Andrew ^d   Boyages, John ^a,e  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

Biopsy; Ductal carcinoma in situ; Long term; Meta analysis; Meta regression analysis; Outcomes; Radiotherapy; Surgery; Systematic review; Tamoxifen

Indexed keywords

TAMOXIFEN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; HUMAN; INTRADUCTAL CARCINOMA; LONG TERM SURVIVAL; MASTECTOMY; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; SURVIVAL PREDICTION; SURVIVAL TIME; SYSTEMATIC REVIEW; ADJUVANT RADIOTHERAPY; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; PATHOLOGY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84946820494     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1904-7     Document Type: Article

References (60)

1. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2004;96:6.
2. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999;85:3.
3. Early Breast Cancer Trialists' Collaborative G, Correa C, McGale P, Taylor C, Wang Y, Clarke M, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039.
4. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2009;1:CD000563.
5. Petrelli F, Barni S. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials. Radiother Oncol. 2011;100:2.
6. Dunne C, Burke JP, Morrow M, Kell MR. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:10.
7. Bijker N, van Tienhoven G. Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective. J Natl Cancer Inst Monogr. 2010;2010:41.
8. Erbas B, Provenzano E, Armes J, Gertig D, Erbas B, Provenzano E, et al. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97:2.
9. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:4.
10. Group EBCC, Group ER, Bijker N, Meijnen P, Peterse JL, Bogaerts J, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:21.
11. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:1.
12. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst Monogr. 2011;103:6.
13. Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat. 2000;62:3.
14. Owen D, Tyldesley S, Alexander C, Speers C, Truong P, Nichol A, et al. Outcomes in patients treated with mastectomy for ductal carcinoma in situ. Int J Radiat Oncol Biol Phys. 2013;85:3.
15. Rakovitch E, Narod SA, Nofech-Moses S, Hanna W, Thiruchelvam D, Saskin R, et al. Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis. Int J Radiat Oncol Biol Phys. 2013;86:3.
16. Vidali C, Caffo O, Aristei C, Bertoni F, Bonetta A, Guenzi M, et al. Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study. Radiat Oncol. 2012;7:177.
17. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW. Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg. 1985;150:1.
18. Tunon-de-Lara C, Lemanski C, Cohen-Solal-Le-Nir C, de Lafontan B, Charra-Brunaud C, Gonzague-Casabianca L, et al. Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk. Eur J Surg Oncol. 2010;36:12.
19. Millis RR, Thynne GS. In situ intraduct carcinoma of the breast: a long term follow-up study. Br J Surg. 1975;62:12.
20. Akashi-Tanaka S, Fukutomi T, Nanasawa T, Matsuo K, Hasegawa T, Tsuda H. Treatment of noninvasive carcinoma: fifteen-year results at the National Cancer Center Hospital in Tokyo. Breast Cancer. 2000;7:4.
21. Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer. 2003;98:10.
22. Simpson T, Thirlby RC, Dail DH. Surgical treatment of ductal carcinoma in situ of the breast. 10- to 20-year follow-up. Arch Surg. 1992;127:4.
23. Wanebo HJ, Huvos AG, Urban JA. Proceedings: Treatment of minimal breast cancer. Cancer. 1974;33:2.
24. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer. 1989;63:4.
25. Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008;109:3.
26. Rudloff U, Brogi E, Brockway JP, Goldberg JI, Cranor M, Wynveen CA, et al. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2009;115:6.
27. Solin LJ, Kurtz J, Fourquet A, Amalric R, Recht A, Bornstein BA, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14:3.
28. Ward BA, McKhann CF, Ravikumar TS. Ten-year follow-up of breast carcinoma in situ in Connecticut. Arch Surg. 1992;127:12.
29. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103:12.
30. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 1994;11:3.
31. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005;103:9.
32. Betsill Jr WL, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA. 1978;239:18.
33. Shaitelman SF, Wilkinson JB, Kestin LL, Ye H, Goldstein NS, Martinez AA, et al. Long-term outcome in patients with ductal carcinoma in situ treated with breast-conserving therapy: implications for optimal follow-up strategies. Int J Radiat Oncol Biol Phys. 2012;83:3.
34. Holmes P, Lloyd J, Chervoneva I, Pequinot E, Cornfield DB, Schwartz GF, et al. Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer. 2011;117:16.
35. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. London: Blackwell Scientific; 1994.
36. Hamza TH, van Houwelingen HC, Stijnen T, Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol. 2008;61:1.
37. Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J. 2008;8:4.
38. Wallis MG, Clements K, Kearins O, Ball G, Macartney J, Lawrence GM. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer. 2012;106:10.
39. Cutuli B, Bernier J, Poortmans P. Radiotherapy in DCIS, an underestimated benefit? Radiother Oncol. 2014;112:1.
40. Darby SC, McGale P, Taylor CW, Peto R, Darby SC, McGale P, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6:8.
41. Patt DA, Goodwin JS, Kuo Y-F, Freeman JL, Zhang DD, Buchholz TA, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23:30.
42. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:11.
43. Smith W, Menon G, Wolfe N, Ploquin N, Trotter T, Pudney D. IMRT for the breast: a comparison of tangential planning techniques. Phys Med Biol. 2010;55(4):1231-41.
44. Park CK, Li X, Starr J, Harris EER. Cardiac morbidity and mortality in women with ductal carcinoma in situ of the breast treated with breast conservation therapy. Breast J. 2011;17:5.
45. Boekel NB, Schaapveld M, Gietema JA, Rutgers EJ, Versteegh MI, Visser O, et al. Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2014;106:8.
46. Fentiman IS, Christiaens MR, Paridaens R, Van Geel A, Rutgers E, Berner J, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39:3.
47. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: A systematic review. J Cancer. 2011;2:1.
48. Cutuli B, Lemanski C, Fourquet A, De Lafontan B, Giard S, Meunier A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer. 2009;100:7.
49. Thomas J, Hanby A, Pinder SE, Ball G, Lawrence G, Maxwell A, et al. Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. Eur J Cancer. 2014;50:11.
50. Staley H, McCallum I, Bruce J, Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev. 2012;10:CD007847.
51. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30:12.
52. Solin LJ, Fourquet A, Vicini FA, Taylor M, Haffty B, Strom EA, et al. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. Eur J Cancer. 2005;41:12.
53. Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31:32.
54. Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:9804.
55. Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:9793.
56. Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77:11.
57. Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28:23.
58. Anastrozole or tamoxifen in treating postmenopausal women with ductal carcinoma in situ who are undergoing lumpectomy and radiation therapy. [ http://www.clinicaltrials.gov/ct2/show/NCT00053898 ]. Accessed 9 November 2015.
59. Radiation therapy with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. [ http://clinicaltrials.gov/ct2/show/results/NCT00769379 ]. Accessed 9 November 2015.
60. Solin L. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. 2011. SABCS.